SM
AZN icon

STF Management’s AstraZeneca AZN Stock Holding History

STF Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$312K Sell
1,697
-2,675
-61% -$469K 0.29% 64
2025
Q3 		$671K Sell
4,372
-109
-2% -$16.5K 0.25% 77
2025
Q2 		$626K Buy
4,481
+117
+3% +$16.4K 0.25% 79
2025
Q1 		$641K Buy
4,364
+3
+0.1% +$434 0.31% 73
2024
Q4 		$571K Buy
4,361
+118
+3% +$16.5K 0.26% 82
2024
Q3 		$661K Sell
4,243
-384
-8% -$62K 0.3% 68
2024
Q2 		$722K Sell
4,627
-221
-5% -$33.3K 0.3% 65
2024
Q1 		$657K Sell
4,848
-62
-1% -$8.21K 0.28% 76
2023
Q4 		$661K Buy
4,910
+162
+3% +$21.1K 0.31% 70
2023
Q3 		$643K Buy
4,748
+2,817
+146% +$385K 0.34% 66
2023
Q2 		$276K Sell
1,931
-1,552
-45% -$228K 0.3% 65
2023
Q1 		$484K Buy
3,483
+1,447
+71% +$195K 0.33% 63
2022
Q4 		$276K Buy
+2,036
New +$255K 0.4% 58

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

STF Management's AZN Position: Q4 2025 in Review

STF Management reduced its AstraZeneca (AZN) stake by 61% in Q4 2025, selling an estimated $469K and leaving 1,697 shares worth $312K. The position accounts for 0.29% of the portfolio, ranked #64.

STF Management first reported a position in AZN in Q4 2022 and has held it in 13 quarters since. The position peaked at $722K in Q2 2024. 1,405 funds tracked by Wall St. Rank hold AZN as of Q4 2025.

  • STF Management held 1,697 shares of AstraZeneca worth $312K as of Q4 2025.
  • STF Management sold 2,675 AstraZeneca shares in Q4 2025, an estimated $469K.
  • AstraZeneca made up 0.29% of STF Management's portfolio in Q4 2025, its #64 holding.
  • STF Management first reported a position in AstraZeneca in Q4 2022 and has held it in 13 quarters since.
  • STF Management's AstraZeneca position peaked at $722K in Q2 2024.
  • 1,405 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2025.

Based on STF Management's 13F filing for Q4 2025, filed 5 Feb 2026.